CureVac Enterprise Value Over E B I T D A from 2010 to 2025
| CVAC Stock | USD 3.91 0.05 1.26% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (1.84) | Current Value (1.93) | Quarterly Volatility 55.3156963 |
Check CureVac NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CureVac NV's main balance sheet or income statement drivers, such as Tax Provision of 80.9 K, Net Interest Income of 6.6 M or Interest Income of 15.6 M, as well as many indicators such as Price To Sales Ratio of 17.07, Dividend Yield of 0.0 or PTB Ratio of 1.77. CureVac financial statements analysis is a perfect complement when working with CureVac NV Valuation or Volatility modules.
CureVac | Enterprise Value Over E B I T D A |
Latest CureVac NV's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of CureVac NV over the last few years. It is CureVac NV's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CureVac NV's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
CureVac Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (80.42) | |
| Geometric Mean | 36.57 | |
| Coefficient Of Variation | (68.78) | |
| Mean Deviation | 50.07 | |
| Median | (122.49) | |
| Standard Deviation | 55.32 | |
| Sample Variance | 3,060 | |
| Range | 121 | |
| R-Value | 0.88 | |
| Mean Square Error | 765.40 | |
| R-Squared | 0.77 | |
| Slope | 10.17 | |
| Total Sum of Squares | 45,897 |
CureVac Enterprise Value Over E B I T D A History
About CureVac NV Financial Statements
CureVac NV stakeholders use historical fundamental indicators, such as CureVac NV's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although CureVac NV investors may analyze each financial statement separately, they are all interrelated. For example, changes in CureVac NV's assets and liabilities are reflected in the revenues and expenses on CureVac NV's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CureVac NV. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (1.84) | (1.93) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out the analysis of CureVac NV Correlation against competitors. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.49 | Revenue Per Share | Quarterly Revenue Growth 0.905 | Return On Assets | Return On Equity |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.